Stockscreener 앱 받기
0.699
1.75%
0.012
시간 외 거래:
.71
0.011
+1.57%
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
NRSN Q1'26 Earnings: revenue estimate is 514.10K USD - TradingView
NeuroSense Therapeutics Ltd. (NRSN) Q2 2025 Earnings: Narrower-than-Expected Loss Marks Progress Amid Clinical-Stage OperationsEarnings Yield Analysis - newsline.com
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC - TipRanks
NeuroSense (Nasdaq: NRSN) secures South Korean patent protection for ALS therapy PrimeC - Stock Titan
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - PR Newswire
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC - TipRanks
Japanese patent extends PrimeC protection to 2042 for NeuroSense (NRSN) - Stock Titan
Japan grants 2042 patent on ALS drug combo: NeuroSense's PrimeC - Stock Titan
Neurosense Therapeutics Ltd (NASDAQ: NRSN) Share Price, NRSN Stock News, NRSN Share Price & Updates - Kalkine
NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC - TipRanks
NeuroSense (NRSN) advances Health Canada discussions on PrimeC ALS regulatory path - Stock Titan
NRSN Q2 2025 Earnings: EPS Beat Signals Progress Amid Development StageFinancial Health Score - newsline.com
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Lift SharesDividend Increase Stocks - The Legal Advocate
NeuroSense Therapeutics (NRSN) Faces 4.5% Decline—Key Support at $0.78 Holds the LinePrice Action Signals - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 3.94%, Pivots Near Key Support at $0.82VWAP Deviation - newsline.com
NeuroSense Therapeutics (NRSN) Edges Higher, Testing Resistance at $0.95PCR Moving Average - The Legal Advocate
NeuroSense trades close to 90 cents as next $1 Nasdaq threshold comes into view - Bez Kabli
Amyotrophic Lateral Sclerosis (ALS) Market Set for Significant - openPR.com
NRSN Q2 2025 Earnings: Narrower Loss Surprises, Shares Gain on Cost DisciplineFinal Results - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 4.56% as Support Levels Are TestedExpert Market Insights - Newser
OutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target Discovery - Yahoo Finance
TradingKey - TradingKey
NRSN (NeuroSense Therapeutics) Q2 loss narrows 6.9% more than expected, but investors await pipeline catalyst update.Expert Verified Trades - newser.com
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - The Globe and Mail
NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve
NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan
NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Niva Russek Blum Net Worth (2026) - GuruFocus
Ferenc Tracik Net Worth (2026) - GuruFocus
Hagit Binder Net Worth (2026) - GuruFocus
Alon Ben Noon Net Worth (2026) - GuruFocus
Revital Mandil Levin Net Worth (2026) - GuruFocus
Tangible book value per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EBIT per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Operating cash flow per share of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NEUROSENSE THERAPEUTICS LTD (NRSN) Earnings History & Surprises - ChartMill
Form 20-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)] - ADVFN
Sentiment Review: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesPortfolio Gains Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Nasdaq Moves: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingPortfolio Value Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Patterns Watch: Is NeuroSense Therapeutics Ltd Equity Warrant part of any ETF2026 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
If You Invested $1,000 in Neurosense Therapeutics Ltd (NRSN) - Stock Titan
Trend Report: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingWeekly Risk Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Bank Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingMarket Weekly Review & Daily Stock Trend Reports - baoquankhu1.vn
Chipmakers Recap: Why is NeuroSense Therapeutics Ltd stock going downEarnings Growth Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Aug Highlights: What are NeuroSense Therapeutics Ltd Equity Warrants earnings expectations2026 Earnings Surprises & Low Risk Entry Point Tips - baoquankhu1.vn
NRSN Analyst Rating Update: D. Boral Capital Maintains 'Buy' Rat - GuruFocus
Inflation Data: Is NeuroSense Therapeutics Ltd Equity Warrant stock undervalued right nowEarnings Summary Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Volatility Watch: Can NeuroSense Therapeutics Ltd Equity Warrant keep up with sector leaders2026 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Breakout Watch: Is NeuroSense Therapeutics Ltd gaining market share2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Income Plays: Is NeuroSense Therapeutics Ltd stock a value trap2026 AllTime Highs & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd stock a buy or sellMarket Trend Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
NeuroSense granted Brazilian patent covering PrimeC composition - TipRanks
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements - marketscreener.com
NeuroSense Wins Long-Term Brazilian Patent Protection for ALS Drug PrimeC - TipRanks
1.27%
1.43%
자본화:
|
볼륨(24시간):